HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael Reusch Selected Research

Anemia

6/2023Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease.
1/2023Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
4/2022Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin.
10/2021Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
10/2021Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
10/2021Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
7/2021Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.
1/2021Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
12/2020Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
4/2020Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael Reusch Research Topics

Disease

15Chronic Renal Insufficiency
06/2023 - 01/2019
13Anemia
06/2023 - 01/2019
11Hypoxia (Hypoxemia)
04/2022 - 01/2019
4Neoplasms (Cancer)
02/2021 - 09/2016
2Heart Failure
01/2023 - 10/2021
2Myocardial Infarction
01/2023 - 10/2021
2Unstable Angina
01/2023 - 10/2021
2Stroke (Strokes)
01/2023 - 10/2021
2Retinal Hemorrhage
04/2022 - 01/2020
2Carcinoma (Carcinomatosis)
02/2021 - 03/2019
1Chronic Kidney Failure (Chronic Renal Failure)
10/2021
1Hypertension (High Blood Pressure)
01/2021
1Adenoma (Adenomas)
03/2019
1Cardiovascular Diseases (Cardiovascular Disease)
01/2019
1Melanoma (Melanoma, Malignant)
09/2016
1Psoriasis (Pustulosis Palmaris et Plantaris)
08/2014
1Seasonal Allergic Rhinitis (Hay Fever)
06/2013
1Hypersensitivity (Allergy)
06/2013

Drug/Important Bio-Agent (IBA)

15roxadustatIBA
06/2023 - 01/2019
11Prolyl-Hydroxylase InhibitorsIBA
04/2022 - 01/2019
4HematinicsIBA
01/2023 - 01/2020
3Hemoglobins (Hemoglobin)IBA
06/2023 - 10/2021
3IronIBA
06/2023 - 01/2020
2omega-Chloroacetophenone (Mace)IBA
01/2023 - 10/2021
2Darbepoetin alfa (Aranesp)FDA Link
10/2021 - 01/2020
2Keratins (Keratin)IBA
02/2021 - 03/2019
2Perilipin-2IBA
02/2021 - 03/2019
2Androgen Receptors (Androgen Receptor)IBA
02/2021 - 03/2019
1Proteins (Proteins, Gene)FDA Link
02/2021
1AntibodiesIBA
02/2021
1LDL Lipoproteins (beta Lipoproteins)IBA
01/2021
1oxidized low density lipoproteinIBA
01/2021
1Mucin-1 (CA 15-3 Antigen)IBA
03/2019
1Indicators and Reagents (Reagents)IBA
01/2017
1Midazolam (Versed)FDA LinkGeneric
09/2016
1Adrenal Cortex Hormones (Corticosteroids)IBA
08/2014
1calcipotriene (calcipotriol)FDA LinkGeneric
08/2014
1VitaminsIBA
08/2014
1Cholecalciferol (Vitamin D3)FDA Link
08/2014
1Anti-Allergic Agents (Antiallergic Agents)IBA
06/2013

Therapy/Procedure

3Renal Dialysis (Hemodialysis)
10/2021 - 01/2020
2Therapeutics
08/2014 - 06/2013
1Peritoneal Dialysis
04/2020
1Self Medication
06/2013